Jay Detsky MD

"Universities shape climate. Leadership is not measured by how quickly a slide is removed; it measured by whether you understand why it never should have been there in the first place" | @MatthewTaub @_UJewishOrg @KishenAnil does not belong as dean @UofTDentistry cc: @UofT

Join myself, @gliomadoc @DrNirLipsman and others in support of @icrf_toronto to learn about incredible advances in brain tumor treatments happening here in Toronto, on Wednesday Feb 25th. icrf.crowdchange.ca/128060

@cpeedell @DrSpratticus @MRoupret @EurUrolOncol @ESTRO_RT @Uroweb Hear me out. If a bunch of prostate rad oncs had an Onion-style satirical journal and came up with an idea how to twist data to *joke* about how we feel urologists see prostate radiation, this is pretty much the article that would ensue. I almost can’t believe it’s not satire

@DrSpratticus @MRoupret @EurUrolOncol @ESTRO_RT @Uroweb Too kind, Daniel. He needs to apologize, resign and retract the paper. There are already urologists quoting it and no doubt it will come up in patient consultations soon. Look at this textbox summary in paper. Shocking. Even quotes wrong number of patients (factor of 4 out!)

As editor-in-chief of @EurUrolOncol I would be happy to offer the possibility to comment, feed the debate and discuss within the journal @ESTRO_RT @Uroweb

@LauraBukavinaMD @EurUrolOncol There should be applause for competent investigators, not disingenuous instigators. This paper adds nothing that we didn't already know, but instead falsely frames the minority subset of patients with serious adverse events as a majority event.

@RicBertolo @DrAndrewLoblaw Hold on. “The sheer number”. And if the registry had a million patients with the same percentage of adverse events that would be worse simply because the absolute number is higher? Seriously?

@DrAndrewLoblaw As we wrote, this is clearly a selected population. That said, compared with the narrative that is often presented, we still find the sheer number of patients captured within a single year to be quite striking.

Well of course you’re going to see a lot of adverse events if you set up a registry and enroll only patients with adverse events! “Men with localized PC previously treated with RT who presented with late (≥6 mo) GU complications requiring urgent medical attention were enrolled”

@DrAndrewLoblaw @dr_vesi LOL. A fancy graphic with percentages of patients with serious toxicity; and this in the abstract. Also, half the patients had surgery and RT and no differentiation for late toxicity between the two, but sold as “late radiation adverse events”

I stand with the great people of Iran and my thoughts are with my friends and colleagues with family there, whom they cannot reach since last week, that they are safe.

A huge pleasure and honor to present in beautiful Israel. Thank you for your hospitality! #hope #HCC #SBRT

Truly a sad day in Australia and across the world

Let’s go Jays!!!! #WANTITALL

@draldehaim @KFSHRC @Alfaisaluniv Well deserved and I can’t imagine someone better suited for the job! Congrats

Honored to be appointed Head of Graduate Medical Education @KFSHRC , Riyadh. Ready to advance our educational programs, foster innovation, and empower the next generation of medical leaders. Let's get to work! @Alfaisaluniv

There are cases of GG1 disease that is still high risk (eg PSA>20) which almost always means higher grade disease was missed at the time of biopsy. GG1 disease is not “associated with int or high risk disease” 🤦‍♂️

This is the most poorly worded tweet from a medical journal I’ve ever seen and completely misconstrues the point of the article, which itself is confusing

✋🏻 When it comes to medical conferences or papers ⚠️ Why do people write posts like this? ✅It makes it really hard to read 👀 Type things out normally; 🚨Just my two cents!

🇮🇱

If you guessed 40–70%, you're right! Want to learn more about this breakthrough in high-grade glioma treatment? Tune in to hear @SahgalArjun on the latest episode of our podcast, Spilling the RT ➡️ bit.ly/4jSo4BD

@gliomadoc @SahgalArjun Clearly they saw my UNITED presentation at ASTRO!

Major League Baseball shrank the strike zone. Margin reduction at it again! ⁦@SahgalArjun⁩ ⁦@jaydetsky⁩. 2 inch mbuffer in the PTV Shrunk to .75 around the 17 inch CTV (plate) nytimes.com/athletic/63281…

@mjlimfat @AANmember Awesome congrats MJ!

@hznus It’s too bad the right parietal lobe is clear but there’s a metastasis in the left parietal lobe!

And some attempts to get it to contour.

🤯 Unlimited, AI-generated practice cases for radiation oncology training—powered by 4o. Game changer or hype? What do you think? Prompt: “A 2x3 grid of highly realistic, clinical-quality brain imaging scans of the same axial slice from a patient with a solitary brain metastasis in the right parietal lobe, commonly treated with stereotactic radiosurgery (SRS). The grid should include the following modalities: T1-weighted MRI, T2-weighted MRI, CEST MRI, DWI MRI, FLAIR MRI, and non-contrast CT. The metastasis should appear as a ring-enhancing lesion on T1, hyperintense on T2 and FLAIR, hypointense on DWI with surrounding vasogenic edema, and visible as a hyperdense or slightly heterogeneous lesion on CT. Anatomical structures should be clear, and the tumor characteristics should be visually consistent across modalities. The background should be black, labels should be in white bold font beneath each scan: ‘T1’, ‘T2’, ‘CEST’, ‘DWI’, ‘FLAIR’, and ‘CT’.”

MATTHEW KNIES 🚨 WITH 0.1 SECONDS LEFT IN THE PERIOD